SAH-p53-8 has further been shown to block the p53-MDMX binding and activate the p53 signaling pathway, thus inhibiting cancer cell viability, inducing apoptosis, and overcoming MDMX-mediated cancer chemoresistance in vitro and in vivo. Here, TP53 is linked to cancer.